{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-001608","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.901895+00:00","generated_at":"2026-06-21T20:43:04.889238+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Scholar Rock Q3 net loss $43.3M ($0.55/share), cash $343.7M, appoints CEO/CMO","bullets":["Net loss of $43.3M ($0.55/share) vs $37.5M loss in Q3 2021; zero revenue vs $5.5M prior year.","Cash, equivalents, and marketable securities $343.7M as of Sep 30, 2022, expected to fund operations into 2025.","Appointed Jay Backstrom as President & CEO (Oct) and Jing Marantz as CMO (Nov).","Amended debt facility with Oxford/SVB adding $25M capacity, extending interest-only period to Nov 2024 and maturity to Nov 2027.","Phase 3 SAPPHIRE trial for apitegromab enrolling ~156 patients; Phase 1 DRAGON shows confirmed PR in ccRCC."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-001608","json":"https://secwatch.observer/filing/0001157523-22-001608.json","markdown":"https://secwatch.observer/filing/0001157523-22-001608.md","text":"https://secwatch.observer/filing/0001157523-22-001608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000115752322001608/0001157523-22-001608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000115752322001608/a52967670.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:43:04.889238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a73f948461267636eb8a3b36d199125c14cfd218","claim":"Scholar Rock Holding Corp reported third quarter ended September 30, 2022 results: revenue $0, net income $43.3 million, EPS $0.55 per share.","evidence_excerpt":"For the quarter ended September 30, 2022, net loss was $43.3 million or $0.55 per share compared to a net loss of $37.5 million or $1.02 per share for the quarter ended September 30, 2021. Revenue was $0 for the quarter ended September 30, 2022, compared to $5.5 million for the quarter ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1727196/000115752322001608/0001157523-22-001608-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$0"},{"label":"Net income","value":"$43.3 million"},{"label":"EPS","value":"$0.55 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}